<?xml version="1.0" encoding="UTF-8"?>
<itemContainer xmlns="http://omeka.org/schemas/omeka-xml/v5" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://omeka.org/schemas/omeka-xml/v5 http://omeka.org/schemas/omeka-xml/v5/omeka-xml-5-0.xsd" uri="https://www.nal.usda.gov/exhibits/speccoll/items/browse?advanced%5B0%5D%5Belement_id%5D=39&amp;advanced%5B0%5D%5Btype%5D=is+exactly&amp;advanced%5B0%5D%5Bterms%5D=R.+L.+Hotchkiss&amp;output=omeka-xml" accessDate="2026-04-10T08:44:47+00:00">
  <miscellaneousContainer>
    <pagination>
      <pageNumber>1</pageNumber>
      <perPage>15</perPage>
      <totalResults>1</totalResults>
    </pagination>
  </miscellaneousContainer>
  <item itemId="2193" public="1" featured="0">
    <fileContainer>
      <file fileId="1286">
        <src>https://www.nal.usda.gov/exhibits/speccoll/files/original/aa6abaf6878d27e12e74c988c9eb36d1.pdf</src>
        <authentication>242f6ba0394f6382357c8938b02daa6d</authentication>
        <elementSetContainer>
          <elementSet elementSetId="4">
            <name>PDF Text</name>
            <description/>
            <elementContainer>
              <element elementId="60">
                <name>Text</name>
                <description/>
                <elementTextContainer>
                  <elementText elementTextId="63235">
                    <text>0114

Item ID Number

°

Author

Webt) K

Corporate Author

Centers for Disease Control (CDC)

.

Report/Article Title Results of a Pilot Study of Health Effects due to 2,3,7,8Tetrachlorodibenzodioxin Contamination - Missouri

JOUmal/BOOk Title

Morbidity and Mortality Weekly Report

Year

1Q

Month/Day

February 10

Color

a

84

Number of Images

4

DeSCrlptOU NotOS

Alvin L

- Young filed this item under the category
"Human Exposure to Phenoxy Herbicides and TCDD"

Thursday, April 05, 2001

Page 1140 of 1180

�33(6) i
54

MMWR

February 10. 1984

Hepatocellular Carcinoma ~ Continued
mented by ultrasonography and CAT scan, was in an elderly man who declined biopsy and
surgery. All patients with tumors were asymptomatic at the time of detection, and all had
rising AFP levels or a single level above 1 ,000 ng/ml. Of the 1 0 remaining people with elevated AFP, one has had low-level elevations (50-90 ng/ml) and is being evaluated, and nine had
transient elevations associated with acute HBV infection. These preliminary results suggest
that AFP screening of HBsAg-positive persons can, at least sometimes, detect PHC at a stage
when surgical resection may be curative.
Reported by L Ingle, MD, S Kilkenny, MD, K Kline, MD, B McMahon. MD, TPaprocki, MD, K Petersen, MD,
Alaska Native Medical Center, Alaska Area Native Health Svc, Indian Health Svc, Anchorage, Alaska;
Arctic Investigations Laboratory, Center for Infectious Diseases, CDC.

Editorial Note: PHC is a leading cause of cancer deaths in much of Asia and Africa.
Worldwide, it is estimated that over 150 million chronic carriers of HBV infection— 900,000
of whom live in the United States— are at risk for developing PHC (4).
In the past, a PHC diagnosis usually followed the onset of symptoms, and the 5-year survival rate approached zero (5). Of the various treatments for PHC, only surgical resection has
resulted in long-term survival. A recent study from the People's Republic of China demonstrated that surgery in asymptomatic patients with tumors less than 5 cm in diameter can result in
improved survival (6).
Well-designed prospective studies are needed to evaluate the use of AFP screening in the
early detection of PHC. These studies should include measures of sensitivity, specificity, and
positive predictive value, as well as an analysis of cost-effectiveness. The preliminary Alaskan
experience is promising and will hopefully result in recommendations concerning the use of
prospective AFP testing among HBsAg carriers.
While early detection of PHC may improve survival rates, detection is only part of the
health-care strategy directed against PHC. Because of the presumed etiologic link between
chronic HBV infection and PHC, preventing PHC may be possible by preventing HBV infection.
The success of future HBV vaccination programs may well determine the future incidence of
PHC.
References
1. Heyward WL, Lanier AP, Bender TR, et al. Primary hepatocellular carcinoma in Alaskan Natives,
1 969-1979. Int J Cancer 1 98 1 ;28:47-50.
2. Schreeder MT, Bender TR, McMahon BJ, et al. Prevalence of hepatitis B in selected Alaskan Eskimo
villages. Am J Epidemiol 1983:118:543-9.
3. Heyward WL, Lanier AP, Bender TR, et al. Early detection of primary hepatocellular carcinoma by
screening for alpha-f etoprotein in high risk families: a case-report. Lancet 1983:11:1 161-2.
4. Report of a WHO meeting. Prevention of liver cancer. In: WHO Technical Report Series No. 691,
1983.
5. Moertel CG. The liver. In: Holland JF, Frei E III, eds. Cancer medicine. 2nd edition. Philadelphia: Lea &amp;
Febiger, 1982:1774-81.
6. Tang Z-y, Yu Y-q, Lin Z-v, Yang B-h, Zhou X-d, Cao Y-z. Clinical research of primary liver cancer: a
10 year (1970-1 979) survey. Chin Med J 1983;96:247-50.

Results of a Pilot Study of Health Effects
due to 2,3,7,8-Tetrachlorodibenzodioxin Contamination — Missouri
In 1971, waste oils containing 2,3,7,8-tetrachlorodibenzodioxin (TCDD) were sprayed on
residential, recreational, and work areas in Missouri to control dust. In several of these areas,
the extent of environmental contamination did not become apparent until late 1982 and into

�Vol. 33/No. 5

MMWR

55

TCDD Contamination - Continued
1983. Starting in January 1983, the Missouri Division of Health and CDC administered approximately 800 Health Effect Survey screening questionnaires to individuals initially solicited
because of potential exposures at residential areas in eastern Missouri. In February, a group of
68 persons considered to have a high probability of exposure (i.e., who lived in, worked at. or
recreated at these areas) and a group of 36 persons considered to have no exposure were
selected after reviewing these questionnaires. These 104 persons received detailed medical
examinations and a series of laboratory tests focused on detecting subclinical effects in key,
target-organ systems (i.e., hepatic, dermatologic, immunologic, and neurologic systems).
Comparisons of these two groups produced no consistent indications of increased disease
prevalence directly related to the putative exposures; no cases of chloracne, overt porphyria
cutanea tarda (PCT)* or precursor conditions of PCT, or soft-tissue sarcomas were seen. An
apparent trend of urinary-tract abnormalities was indicated by an increased prevalence of selfreported kidney/urinary problems, a higher proportion of leukocyturia, and a greater prevalence of microscopic hematuria in the group at high risk of exposure. None of the findings
from the medical histories or the immune-function assays demonstrated statistically significant differences. There was, however, an indication of an increased prevalence of T4/T8-cell
ratios less than 1.0 in the high-risk group. No significant differences in standard and specialized liver-function test results were detected.
This pilot study of a group of individuals presumed to be at high risk of exposure was intended to provide a perspective on the types and degrees of abnormalities likely to be seen in
such TCDD exposures. The results appear negative, but no overall definitive conclusion
should be based solely on this initial study. The insights provided need to be examined in
more refined epidemiologic studies using different designs and strategies (especially in larger,
more homogeneous population groups in which exposure status can be better characterized).
These studies should be focused primarily, but not exclusively, on discerning any effects on
the immune and neurologic systems and the urinary tract and liver.
Reported by K Webb, S Ayres. ft Slavin. A Knutsen, S Roodman, St. Louis University, WB Gedney, St.
Joseph Hospital, Kirkwood, WSchramm, PL Hotchkiss, R Miller, HD Donne/I, State Epidemiologist, Missouri Div of Health; Special Studies Br, Chronic Diseases Div, Clinical Chemistry Div, Center for Environmental Health, CDC.

Editorial Note: Animal toxicity studies are commonly used to predict health effects in
humans (although the existence of species-specific and even organ-specific effects of TCDD
make extrapolations tenuous). The organ systems most prominently affected in animals are
the liver (acute toxicity and hepatocarcinogenesis), the immune system (thymic atrophy and
decreased cell-mediated immunity), and the skin (chloracne-like changes); effects on reproduction have also been noted (1,2).
Most direct knowledge of TCDD effects on human health has been obtained from workers
exposed to dioxin during the production or subsequent handling of 2,4,5-trichlorophenol
(2,4,5-TCP) or 2,4,5-trichlorophenyoxyacetic acid (2,4,5-T) (3). In some workplaces, exposed persons had chloracne but no systemic illnesses; other reports have noted that workers
fatigued easily and experienced weight loss, myalgias, insomnia, irritability, and decreased
libido. The liver has been shown to become tender and enlarged, and sensory changes, particularly in the lower extremities, have been reported. Total serum lipids may be increased, and
the prothrombin times may be prolonged (4). PCT has also been observed (5). The most
specific of the dioxin-related findings are chloracne (which can also be caused by other structurally similar compounds, such as polychlorinated biphenyls [PCBs] and chlorinated
naphthalenes) and PCT (which also has a variety of potential causes). A number of studies ad"An acquired form of porphyria characterized by chronic skin lesions and other symptoms.

�56

MMWR

February 10,1984

TCDD Contamination - Continued
dressing the association of TCDD exposures to soft-tissue sarcoma have been conducted in
the industrial setting. These include two case-control studies in Sweden in which investigators
reported a sixfold increase in the risk of soft-tissue sarcomas among persons exposed to
chlorphenols and phenoxy herbicides (6).
Information on health effects involving nonoccupational environmental exposure is sparse.
In 1976, after an explosion at a Seveso, Italy, chemical plant, chloracne developed in exposed
children; some elevated liver-function test results were detected in the exposed population,
and the incidence of abnormal nerve conduction tests was reported significantly elevated in
subjects with chloracne (7). In Missouri, after playing in dirt in a riding arena contaminated
with up to 33 parts per million TCDD, a child had hemorrhagic cystitis (8).
Public health policy in situations such as this environmental contamination with TCDD
must continue to focus on the prevention of any potential health effects (particularly delayed
or long-term), even if effects are not demonstrated in a pilot study. For this reason, appropriate efforts to prevent human exposure must continue, in this and other similar situations, until
a more complete understanding of public health risks is obtained.
(Continued on page 61)
TABLE I. Summary-cases specified notifiable diseases. United States
Sth Week Ending
Disease

February 4,
1984

Acquired Immunodeficiency Syndrome (AIDSI
Aseptic meningitis
Encephalitis: Primary (arthropod-borne
&amp;un«pec.l
Pott-infectious
Gonorrhea: Civilian
Military
Hepatitis:
Type A
TypeB

Non A, Non B
Unspecified
Legionellosis
Leprosy
Malaria
Measles: Total1
Indigenous
Imported
Meningococcal infections: Total
Civilian
Military
Mumps
Pertussis
Rubella (German measles)
Syphilis (Primary &amp; Secondary): Civilian
Military
Toxic Shock syndrome
Tuberculosis
Tularemia
Typhoid fever
Typhus fever, tick-borne (RMSF)
Rabies, animal

I

February 5.
1983

Cumulativ e, Sth Week Ending
Median
1979-1983

February 4, 1 February 5,
1984

1

N
369

64
3

83
5

78,872
2,009

91,339

1,890
1,937
281
517
31
15
53
137
132
5
232
232
291
109
37
2.687
33
28
1,585
5
19
6
257

2,305

78
9
92.424
2.762
2.250
1.630
N
868
N
14
57
164
N
N
273
269
1
472
90
207
2,915
42
N
1,943
11
30
6
422

N
93

N
59

257
440

20
-

12

12
2
19,765
622
543
361
N
183
N
4
14
40
N
N
62
62
104
29
39
645
7
N
471
2
8
1
96

379
443
474
67
121
5
1
14
91
91
59
59

60
14
8
592
2
8
395
2
2
70

17,887
427
543
387
79
149
11
2
14
3
1
2
66
55
1
75
30
23
652
6
8
442
5
4
99

Mftdifln
1979-1983

N
450

51
86

14,831

1983

2,417
1,930
269
677
49
26
52
40
28
12
266
258

a

381
90
72
3,350
51
43
1,726
13
30
6
443

TABLE II. Notifiable diseases of low frequency. United States
Cum. 1984

Cum. 1 984

Anthrax
Botulism: Foodborne
Infant (Calif. 1)
5
Other
1
Brucellosis (Upstate N.Y. 1 , Ohio 1 , Mo. 1 , Va. 1 , Calif. 2)
11
Cholera
Congenital rubella syndrome
Diphtheria
Leptospirosis (Ohio 1 , Hawaii 1 1
2

Plague (Wash. 1 1
Poliomyelitis: Total
Paralytic
Psittacosis (Upstate N.Y. 2)
Rabies, human
Tetanus (Kans. 1 , Calif . 1 )
Trichinosis
Typhus fever, flea-borne (endemic, murine)

•There were no cases of internationally imported measles reported for this week.

1
6
2
2
2

�Vol. 33/No. 5

MMWR

61

TCDD Contamination — Continued
deferences
1. Gupta BN, Vos JG, Moore JA, Zinkl JG, Bullock BC. Pathologic effects of 2,3,7,8-Tetrachlorodibenzo-/»-dioxin in laboratory animals. Environ Hlth Per 1973;5:125-40.
2. Kociba RJ, Keyes DG, Beyer JE, et al. Results of a two-year chronic toxicity and oncogenicity study of
2,3,7,8-Tetrachlorodibenzo-p-dioxin in rats. Toxicol Appl Pharmacol 1978;46:279-303.
3. Kimbrough RD, ed. Topics in environmental health. Volume 4. Halogenated biphenyls, terphenyls,
naphthalenes, dibenzodioxins and related products. Amsterdam, The Netherlands: Elsevier/North
Holland Biomedical Press. 1980.
4. Jensen NE, Walker AE. Chloracne: three cases. Proc R Soc Med 1972;65:687-8.
5. Poland AP, Smith D, Metter G, Possick P. A health survey of workers in a 2,4-D and 2,4,5-T plant
with special attention to chloracne, porphyria cutanea tarda, and psychologic parameters. Arch Environ Health 1971 ;22:316-27.
6. Eriksson M, Hardell L, Berg NO, Moller T, Axelson 0. Soft-tissue sarcomas and exposure to chemical
substances: a case-referent study. Br J Ind Med 1981 ;38:27-33.
7. Reggiani G. Acute human exposure to TCDD in Seveso, Italy. J Toxicol Environ Health 1980:6:27-43
8. Carter CD, Kimbrough RD, Liddle JA, et al. Tetrachlorodibenzodioxin: an accidental poisoning episode
in horse arenas. Science 1975:188:738-40.

Current Trends
Measles Surveillance — Canada
A provisional total of 915 measles cases was reported in Canada for 1983. This appears
to be the lowest incidence reported since national reporting of measles began in 1924.
However, complete data are available only through 1982.
In 1982, 1,064 cases of measles were reported in Canada, a rate of 4.3 cases per
100,000 population. Compared with 1981 and 1980, this reflects a 55% and a 92%
reduction, respectively, and a 99% reduction compared with the 10-year prevaccine period
1949-1958 (Figure 1).
All provinces except Prince Edward Island reported measles cases in 1982. Although Ontario accounted for the largest proportion of cases (48%), it reported a 41% reduction in incidence rate compared with 1981.
The age distribution of measles patients in 1982 was available for all provinces except
Ontario, for which data were available from January to June 1982. Children under 1 year of
age accounted for 19% of cases; under 5 years, 27%; and under 10 years, 75%. The highest
rate (43 cases per 100,000 persons) occurred among infants, followed by preschoolers (1-4
years), with a rate of 15.1 per 100,000 persons. In Ontario, 21 % of children were less than 5
years old; school-aged children (5-19 years) accounted for 73% of 224 cases.
All provinces are attempting to eliminate measles either by compulsory vaccination at
school entry or by voluntary approaches, and some have reported that up to 95% of children
are now immunized by the time they reach school age. New Brunswick and Ontario
(representing 39% of Canada's population) introduced legislation in 1981 and 1982,
respectively, making immunization against measles and five other diseases (diphtheria,
tetanus, pertussis, polio, and rubella) compulsory for school attendance.
Reported by Health and Welfare, Canada; Weekly Epidemiological Record 1983:58:331-2, World
Health Organization; Div of Immunization, Center for Prevention Svcs, CDC.

�</text>
                  </elementText>
                </elementTextContainer>
              </element>
            </elementContainer>
          </elementSet>
        </elementSetContainer>
      </file>
    </fileContainer>
    <collection collectionId="30">
      <elementSetContainer>
        <elementSet elementSetId="1">
          <name>Dublin Core</name>
          <description>The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.</description>
          <elementContainer>
            <element elementId="50">
              <name>Title</name>
              <description>A name given to the resource</description>
              <elementTextContainer>
                <elementText elementTextId="4687">
                  <text>Alvin L. Young Collection on Agent Orange</text>
                </elementText>
              </elementTextContainer>
            </element>
            <element elementId="41">
              <name>Description</name>
              <description>An account of the resource</description>
              <elementTextContainer>
                <elementText elementTextId="49809">
                  <text>&lt;p style="margin-top: -1em; line-height: 1.2em;"&gt;The Alvin L. Young Collection on Agent Orange comprises 120 linear feet and spans the late 1800s to 2005; however, the bulk of the coverage is from the 1960s to the 1980s and there are many undated items. The collection was donated to Special Collections of the National Agricultural Library in 1985 by Dr. Alvin L. Young (1942- ). Dr. Young developed the collection as he conducted extensive research on the military defoliant Agent Orange. The collection is in good condition and includes letters, memoranda, books, reports, press releases, journal and newspaper clippings, field logs and notebooks, newsletters, maps, booklets and pamphlets, photographs, memorabilia, and audiotapes of an interview with Dr. Young.&lt;/p&gt;&#13;
&lt;p&gt;For more about this collection, &lt;a href="/exhibits/speccoll/exhibits/show/alvin-l--young-collection-on-a"&gt;view the Agent Orange Exhibit.&lt;/a&gt;&lt;/p&gt;</text>
                </elementText>
              </elementTextContainer>
            </element>
          </elementContainer>
        </elementSet>
      </elementSetContainer>
    </collection>
    <itemType itemTypeId="1">
      <name>Text</name>
      <description>A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.</description>
      <elementContainer>
        <element elementId="52">
          <name>Box</name>
          <description>The box containing the original item.</description>
          <elementTextContainer>
            <elementText elementTextId="14565">
              <text>045</text>
            </elementText>
          </elementTextContainer>
        </element>
        <element elementId="53">
          <name>Folder</name>
          <description>The folder containing the original item.</description>
          <elementTextContainer>
            <elementText elementTextId="14567">
              <text>1140</text>
            </elementText>
          </elementTextContainer>
        </element>
        <element elementId="54">
          <name>Series</name>
          <description>The series number of the original item.</description>
          <elementTextContainer>
            <elementText elementTextId="14571">
              <text>Series III Subseries I</text>
            </elementText>
          </elementTextContainer>
        </element>
      </elementContainer>
    </itemType>
    <elementSetContainer>
      <elementSet elementSetId="1">
        <name>Dublin Core</name>
        <description>The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.</description>
        <elementContainer>
          <element elementId="39">
            <name>Creator</name>
            <description>An entity primarily responsible for making the resource</description>
            <elementTextContainer>
              <elementText elementTextId="14555">
                <text>Webb, K.</text>
              </elementText>
              <elementText elementTextId="14556">
                <text>S. Ayres</text>
              </elementText>
              <elementText elementTextId="14557">
                <text>R. Slavin</text>
              </elementText>
              <elementText elementTextId="14558">
                <text>A. Knutsen</text>
              </elementText>
              <elementText elementTextId="14559">
                <text>S. Roodman</text>
              </elementText>
              <elementText elementTextId="14560">
                <text>W. B. Gedney</text>
              </elementText>
              <elementText elementTextId="14561">
                <text>W. Schramm</text>
              </elementText>
              <elementText elementTextId="14562">
                <text>R. L. Hotchkiss</text>
              </elementText>
              <elementText elementTextId="14563">
                <text>R. Miller</text>
              </elementText>
              <elementText elementTextId="14564">
                <text>H. D. Donnell</text>
              </elementText>
            </elementTextContainer>
          </element>
          <element elementId="41">
            <name>Description</name>
            <description>An account of the resource</description>
            <elementTextContainer>
              <elementText elementTextId="14566">
                <text>&lt;strong&gt;Corporate Author: &lt;/strong&gt;Centers for Disease Control (CDC)</text>
              </elementText>
            </elementTextContainer>
          </element>
          <element elementId="48">
            <name>Source</name>
            <description>A related resource from which the described resource is derived</description>
            <elementTextContainer>
              <elementText elementTextId="14568">
                <text>Morbidity and Mortality Weekly Report</text>
              </elementText>
            </elementTextContainer>
          </element>
          <element elementId="40">
            <name>Date</name>
            <description>A point or period of time associated with an event in the lifecycle of the resource</description>
            <elementTextContainer>
              <elementText elementTextId="14569">
                <text>February 10 1984</text>
              </elementText>
            </elementTextContainer>
          </element>
          <element elementId="50">
            <name>Title</name>
            <description>A name given to the resource</description>
            <elementTextContainer>
              <elementText elementTextId="14570">
                <text>Results of a Pilot Study of Health Effects due to 2,3,7,8-Tetrachlorodibenzodioxin Contamination - Missouri</text>
              </elementText>
            </elementTextContainer>
          </element>
          <element elementId="49">
            <name>Subject</name>
            <description>The topic of the resource</description>
            <elementTextContainer>
              <elementText elementTextId="14572">
                <text>dioxin</text>
              </elementText>
              <elementText elementTextId="14573">
                <text>soft tissue sarcoma</text>
              </elementText>
              <elementText elementTextId="14574">
                <text>porphyria</text>
              </elementText>
              <elementText elementTextId="14575">
                <text>chloracne</text>
              </elementText>
            </elementTextContainer>
          </element>
        </elementContainer>
      </elementSet>
    </elementSetContainer>
    <tagContainer>
      <tag tagId="1">
        <name>ao_seriesIII</name>
      </tag>
    </tagContainer>
  </item>
</itemContainer>
